Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Hypophosphatemia after CAR-T cell therapy: a prospective study of inflammation, tubular injury and phosphate handling. Local targets link to admitted publications; unresolved targets remain external evidence.
Long-term outcomes following CAR T cell therapy: what we know so far
10.1038/s41571-023-00754-1 · 2023 · External reference
CAR T-cell therapy in autoimmune diseases
10.1016/s0140-6736(23)01126-1 · 2023 · External reference
Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1
10.1172/jci150211 · 2021 · External reference
Toxicities following CAR-T therapy for hematological malignancies
10.1016/j.ctrv.2022.102479 · 2022 · External reference
Acute kidney injury following CAR-T cell therapy: a nephrologist’s perspective
10.1093/ckj/sfae359 · 2025 · External reference
Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma
10.1053/j.ajkd.2019.10.011 · 2020 · External reference
Hypophosphatemia due to increased effector cell metabolic activity is associated with neurotoxicity symptoms in CD19-targeted CAR T-cell therapy
10.1158/2326-6066.cir-22-0418 · 2022 · External reference
CAR-T cells and the kidney: insights from the WHO safety database
10.1007/s40259-023-00599-1 · 2023 · External reference
Prospective evaluation of CAR-T cell therapy-related proteinuria and kidney dysfunction
10.1093/ckj/sfaf270 · 2025 · External reference
Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T-cell therapy
10.1111/bjh.18504 · 2023 · External reference
Addition of phosphorous and IL6 to m-EASIX score improves detection of ICANS and CRS, as well as CRS progression
10.3390/cancers17060918 · 2025 · External reference
Phosphorus disruption is associated with the incidence and severity of neurotoxicity symptoms in CD19-targeted CAR-T cell therapy: a pooled clinical trial analysis
10.1182/blood-2023-182138 · 2023 · External reference
Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease
10.1016/j.kint.2018.02.026 · 2018 · External reference
New creatinine- and cystatin C-based equations to estimate GFR without race
10.1056/nejmoa2102953 · 2021 · External reference
Hypophosphatemia in cancer patients
10.1093/ckj/sfab078 · 2021 · External reference
ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
10.1016/j.bbmt.2018.12.758 · 2019 · External reference
EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome
10.1016/j.clinph.2024.04.014 · 2024 · External reference
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
10.1200/jco.2013.54.8800 · 2014 · External reference
The Endothelial Activation and Stress Index (EASIX) score is an independent prognostic factor in patients with diffuse large B-cell lymphoma
10.1186/s12885-022-09915-4 · 2022 · External reference
International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma
10.1056/nejm199309303291402 · 1993 · External reference
Incidence and risk factors for acute kidney injury after chimeric antigen receptor T-cell therapy
10.1016/j.mayocp.2022.05.018 · 2022 · External reference
Acute kidney injury after the CAR-T therapy tisagenlecleucel
10.1053/j.ajkd.2020.08.017 · 2021 · External reference
Acute kidney injury following chimeric antigen receptor T-cell therapy: epidemiology, mechanism and prognosis
10.1016/j.clim.2024.110311 · 2024 · External reference
Inflammatory cytokines induce apoptotic and necrotic cell shedding from human proximal tubular epithelial cell monolayers
10.1046/j.1523-1755.2002.t01-1-00456.x · 1999 · External reference
Interaction between systemic inflammation and renal tubular epithelial cells
10.1093/ndt/gfu046 · 2014 · External reference
The complex interplay between kidney injury and inflammation
10.1093/ckj/sfaa164 · 2020 · External reference
Long-term tubular dysfunction in childhood cancer survivors; DCCSS-LATER 2 renal study
10.3390/cancers14112754 · 2022 · External reference
Incidence and aetiology of renal phosphate loss in patients with hypophosphatemia in the intensive care unit
10.1007/s00134-013-2970-4 · 2013 · External reference
Severe hypophosphatemia following idecabtagene vicleucel regardless of the severity of cytokine release syndrome
10.1016/j.jcyt.2024.12.014 · 2025 · External reference
Routine monitoring of CAR-T-cells expansion and persistence in patients with aggressive large B-cell lymphoma by flow cytometry: a single-center experience
10.1002/hon.70139 · 2025 · External reference
Hypophosphatemia correction reduces ICANS incidence and duration in CAR T-cell therapy: a pooled clinical trial analysis
10.1158/2767-9764.crc-24-0250 · 2024 · External reference
